AZ rolls with second blood cancer launch, this time for Lumoxiti by Carly Helfand Wednesday, December 12, 2018 For the second straight year, AstraZeneca is spending the fall launching a hemo-oncology drug.
AZ's Calquence found success in MCL. Will CLL follow? by Carly Helfand Wednesday, December 5, 2018 Just a year after approval, AZ’s Calquence is giving Imbruvica a run for its money in MCL. But the British drugmaker doesn’t want to stop there.
FDA clears AZ's Lumoxiti in rare leukemia by Angus Liu Friday, September 14, 2018 The CD22-directed cytotoxin treatment is AstraZeneca's second approved blood cancer asset, with peak sales estimated at about $500 million.
AbbVie, J&J score early nod for Imbruvica in rare cancer by Eric Sagonowsky Monday, August 27, 2018 Months ahead of the FDA decision date, the agency approved AbbVie and J&J's Imbruvica, plus Roche's Rituxan, to treat adults with a rare blood cancer.
J&J, AbbVie's Imbruvica speeds toward another FDA nod by Carly Helfand Tuesday, June 26, 2018 Imbruvica is the only treatment for Waldenström's macroglobulinemia patients. But before competition hits, its makers are pushing for a wider market.
Vote ‘no’ on AstraZeneca’s CEO bonus, proxy firm says by Arlene Weintraub Tuesday, May 8, 2018 AstraZeneca slashed CEO Pascal Soriot’s total pay by 34% in 2017, but that cut wasn’t deep enough for one influential voice on corporate governance.
J&J, AbbVie tout Imbruvica data in the face of a new AZ threat by Carly Helfand Monday, December 11, 2017 J&J and AbbVie racked up new long-term Imbruvica data that will come in handy as they try to ward off a new AstraZeneca competitor.
